Platform to be used to generate bi-specific antibodies against immuno-oncology targets
NEW YORK, NY, USA I December 14, 2015 I Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer today announced new data with a novel bi-specific antibody in a poster presentation at IBC’s Antibody Engineering & Therapeutics Conference in San Diego, CA. Immune’s poster is titled “Design and Validation of a Novel Tetravalent IgG1-like Bi-Specific Antibody Format” and was on display in the exhibit hall December 8-10, 2015 at the San Diego Convention Center.
In this study, Immune described positive developments with a novel platform for production of tetravalent IgG1-like bi-specific antibodies (bsAb). The prototype bi-specific antibody retained effector functions and mediated redirect killing of target cells by cytokine induced killer T cells demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. The newly developed platform will be further used to generate novel bi-specific antibodies against immune-oncology targets.
The poster was presented by Boris Shor, PhD, executive director R&D, Immune Pharmaceuticals and Jean Kadouche, PhD, a scientific co-founder of Immune Pharmaceuticals. This work was developed by a collaborative European consortium (BMC) led by Dr. Kadouche and funded by a European grant.
For poster request, please contact boris.shor@immunepharma.com
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn’s disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporin A for the treatment of psoriasis and atopic dermatitis. Immune’s oncology pipeline includes, bi-specific antibodies nanotherapeutics, including NanomAbs®, and several mid-to late stage small molecules .Immune’s non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune’s website at www.immunepharmaceuticals.com.
SOURCE: Immune Pharmaceuticals
Post Views: 134
Platform to be used to generate bi-specific antibodies against immuno-oncology targets
NEW YORK, NY, USA I December 14, 2015 I Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune” or the “Company”) a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer today announced new data with a novel bi-specific antibody in a poster presentation at IBC’s Antibody Engineering & Therapeutics Conference in San Diego, CA. Immune’s poster is titled “Design and Validation of a Novel Tetravalent IgG1-like Bi-Specific Antibody Format” and was on display in the exhibit hall December 8-10, 2015 at the San Diego Convention Center.
In this study, Immune described positive developments with a novel platform for production of tetravalent IgG1-like bi-specific antibodies (bsAb). The prototype bi-specific antibody retained effector functions and mediated redirect killing of target cells by cytokine induced killer T cells demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. The newly developed platform will be further used to generate novel bi-specific antibodies against immune-oncology targets.
The poster was presented by Boris Shor, PhD, executive director R&D, Immune Pharmaceuticals and Jean Kadouche, PhD, a scientific co-founder of Immune Pharmaceuticals. This work was developed by a collaborative European consortium (BMC) led by Dr. Kadouche and funded by a European grant.
For poster request, please contact boris.shor@immunepharma.com
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn’s disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporin A for the treatment of psoriasis and atopic dermatitis. Immune’s oncology pipeline includes, bi-specific antibodies nanotherapeutics, including NanomAbs®, and several mid-to late stage small molecules .Immune’s non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune’s website at www.immunepharmaceuticals.com.
SOURCE: Immune Pharmaceuticals
Post Views: 134
